 |
 | Unfractionated Heparin Therapy |
| |  | Protocols for Heparin Therapy Based on aPTT |
| | | Protocols for Heparin Therapy Based on Heparin Dose Response Curve |
| | | Resistance to Heparin Therapy |
| | | Heparin Anticoagulation During Slow, Continuous Therapies for Renal Failure |
| Coagulation Factor Deficiency |
| |  | Factor VIII Levels and Hemophilia A |
| | | Clinical Findings in a Patient with an Hereditary Deficiency of Factor XIII |
| | | Clinical Findings in a Patient with an Hereditary Deficiency of Factor XII |
| | | Clinical Findings in a Patient with an Hereditary Deficiency of Factor XI |
| | | Titer of VIII Inhibitor and Response to Factor VIII Replacement in Hemophilia A |
| | | Indications for Screening a Patient with Hemophilia A for a Factor VIII Inhibitor |
| | | Clinical Findings in a Patient with a Factor XI Inhibitor |
| | | Clinical Findings in a Patient with an Hereditary Deficiency of Factor VII |
| | | Clinical Findings in a Patient with an Hereditary Deficiency of Factor X |
| | | Clinical Findings in a Patient with an Acquired Deficiency of Factor X |
| | | Clinical Findings in a Patient with an Hereditary Deficiency of Factor V |
| | | Clinical Findings in a Patient with an Acquired Factor V Deficiency |
| | | Clinical Findings in a Patient with an Hereditary Deficiency of Factor II (Prothrombin) |
| | | Identification of a Patient with a Hereditary Deficiency of Prekallikrein and/or High Molecular Weight Kininogen |
| | | Clinical Features of Hereditary Deficiency of Factor IX (Hemophilia B) |
| | | Hemophilia A or B in a Female |
| | | Types of Familial Multiple Coagulation Factor Deficiency (FMFD) |
| | | Clinical Features of a Factor IX Inhibitor |
| In Vivo Tests of Platelet and Vascular Function |
| | | Predicting the Bleeding Time from the Platelet Count |
| | | Tourniquet Test (Capillary Fragility Test of Hess, Rumpel-Leede Test) |
| Oral and Parenteral Anticoagulant Therapy |
| | | Algorithm of Vadher et al for Dosing Oral Anticoagulants and Scheduling Followup |
| | | Dosing Algorithm of Ryan et al (Coventry or Warwickhire Method) for Oral Anticoagulants |
| | | Dosing Oral Anticoagulants Using the Hillingdon Method |
| | | Induction and Maintenance Dosing of Oral Anticoagulants Using the Method of Fennerty et al |
| | | Adjustment in the Daily Warfarin Dose for a Patient Receiving Long-Term Amiodarone Therapy |
| | | Predictor Score of Absher et al for a Patient's Warfarin Dose Requirement |
| | | Model of Tham et al for Determining the Daily Dose of Warfarin to Give to an Asian Based on Genotypic Analysis of Vitamin K Eposoxide Reductase Complex and Cytochrome P450 2C9 |
| | | Models of Sconce et al for Determining the Daily Dose of Warfarin to Give That Include Genotypic Analysis of CYP2C9 and VKORC1 |
| | | Model of Kamali et al for Determining Warfarin Dose in a Patient Based on CYP2C9 Genotype |
| | | Warfarin (Coumadin) Resistance |
| | | Model of Zhu et al for Determining a Patient's Daily Dose Requirement for Warfarin |
| | | Parenteral Administration of Warfarin |
| Monitoring Anticoagulant Therapy |
| | | International Normalized Ratio (INR) |
| | | Estimating the Percent Prothrombin Complex Activity from the INR |
| | | Indications for Using an Alternative Method to the PT or INR for Monitoring Warfarin Therapy in a Patient with a Lupus Anticoagulant |
| Adjusting the Amount of Specimen Anticoagulant for an Elevated Hematocrit |
| | | Adjusting the Amount of Specimen Anticoagulant for an Elevated Hematocrit |
| Activated Protein C (APC) Resistance Ratio |
| | | Activated Protein C (APC) Resistance Ratio |
| Protein S and Protein C |
| | | Protein S and C Levels in Patients Receiving Coumadin Therapy |
| | | Neonatal Purpura Fulminans Associated with Congenital Protein C Deficiency |
| | | Conditions Associated with Acquired Deficiency of Protein S and/or Protein C |
| Assessing Platelet Activation |
| | | Beta-Thromboglobulin to Platelet Factor 4 Ratio |
| Diagnosis and Management of Deep Vein Thrombosis |
| | | Probability of Deep Vein Thrombosis |
| | | Screening Tests for Exclusion of Deep Vein Thrombosis |
| | | Risk of Deep Vein Thrombosis and Pulmonary Embolism in a Surgical Patient |
| | | Risk Factor Score of Weiss and Bernstein for Venous Thromboembolism in Obstetric Patients |
| | | Indications for Placement of an Inferior Vena Cava Filter in a Patient with Deep Vein Thrombosis |
| | | Clinical Prediction Index of Kahn et al for Deep Vein Thrombosis in Patients with Leg Symptoms |
| | | Risk Assessment Profile (RAP) of Greenfield et al for Venous Thromboembolism in Adult Trauma Patients |
| | | Indications for Prophylactic Placement of an Inferior Vena Cava Filter in a Trauma Patient |
| | | Discriminant Formula of Clayton et al for Prediction of Post-Operative Deep Vein Thrombosis |
| | | Factors Justifying an Extensive Evaluation in a Patient with Idiopathic Deep Vein Thrombosis |
| | | Pseudothrombophlebitis Associated with a Baker's Cyst |
| | | Reporting Standards of the International Consensus Committee on Chronic Venous Disease for Risk of Acute Lower Extremity Thrombosis |
| | | Reporting Standards of the International Consensus Committee on Chronic Venous Disease for Describe the Extent of Thrombosis in a Lower Extremity |
| | | Modification of Cafferata et al to the Reporting Standards of the ICS on CVT for Risk of Acute Lower Extremity Thrombosis Associated with Trauma |
| | | Duration of Therapy for a Patient with Deep Vein Thrombosis |
| | | Exclusion Criteria for Home (Outpatient) Therapy of Acute Deep Vein Thrombosis |
| | | Algorithm of Gorman et al for the Investigation of Deep Vein Thrombosis |
| | | Diagnosis of Thrombosis of the Axillary and Subclavian Veins |
| | | Diagnosis of Paget-von Schroetter Syndrome with Axillosubclavian Venous Thrombosis (Exertional Thrombosis, Venous Type Thoracic Outlet Obstruction) |
| | | Algorithm of Knudson et al for Venous Thromboembolism Prophylaxis in a Trauma Patient |
| | | Risk Factors of Vavilala et al for Venous Thromboembolism in Pediatric Trauma Patients |
| | | Predictors of Goldenberg et al for a Poor Outcome in a Child with Thrombosis |
| | | Clinical Findings Associated with Severe Deep Vein Thrombosis in a Lower Extremity (Phlegmasia and Venous Gangrene) |
| | | Risk Factors of Cook et al for Deep Vein Thrombosis in a Patient in the Intensive Care Unit (ICU) |
| | | Predictors of Iskander et al for Propagation of Deep Vein Thrombosis Above the Knee in a Trauma Patient |
| | | Risk Factors of Hansson et al for Recurrent Deep Vein Thrombosis |
| | | Risk Assessment Scorecard of Lutz et al for Venous Thromboembolism |
| | | Scoring System of Bjorgell and Robertson for Grading the Extent of Deep Leg Vein Thrombosis |
| | | Venographic Classification of Marder et al for Quantifying Venous Thrombosis in a Leg |
| | | Venographic Classification of Marder et al for Quantifying Venous Thrombosis in an Arm |
| | | Venographic Classification of Arnesen et al for Quantifying Venous Thrombosis in a Leg |
| | | Swelling to Pain (S/P) Ratio of Lundh and Fagher for Evaluating a Patient for a Deep Vein Thrombosis in the Lower Leg |
| | | Risk Score of Rogers et al for Predicting Venous Thromboembolism in a General or Vascular Surgery Patient Based on the Patient Safety in Surgery Study |
| | | Clinical Features of Mondor's Disease (Thrombophlebitis in a Subcutaneous Vein of the Breast) |
| | | Risk Factors for Deep Vein Thrombosis in an HIV-Positive Patient |
| Bleeding Associated with Anticoagulant, Antiplatelet or Antithrombotic Therapy |
| | | Classification of Simonneau et al for Anticoagulation-related Bleeding |
| | | Risk Score of Landefeld et al for Anticoagulant-related Major Bleeding in Hospitalized Patients |
| | | Utrecht Bleeding Risk Score During Treatment of Acute Venous Thromboembolism |
| | | Risk Factors for Bleeding During Warfarin Therapy |
| | | Risk Score of Kuijer et al for Bleeding During Anticoagulant Treatment for Venous Thromboembolism |
| | | Contraindications to Anticoagulant Therapy |
| | | Bleeding Risk Indices of van der Meer et al |
| | | Risk Score of Landefeld and Goldman for Warfarin-Associated Major Bleeding in Outpatients |
| | | The Bleeding Severity Index of Landefeld et al for Bleeding Caused by Medical Therapy |
| | | Risk Factors of Walker and Jick for Bleeding During Heparin Therapy |
| | | Clinical Features of a Retroperitoneal Hematoma in an Anticoagulated Patient |
| | | Risk Factors of Alexander et al for an Excessive Dose of a Glycoprotein IIb/IIIa Inhibitor with Bleeding During the Treatment of Non-ST Segment Elevation Acute Coronary Event |
| | | Criteria of Graafsma et al for Anticoagulant-Related Bleeding with a Bleeding Severity Index |
| | | The Outpatient Bleeding Risk Index of Beyth et al |
| | | Criteria of Montalescot et al for Major and Minor Bleeding During Heparin Therapy |
| | | Bleeding Risk Model of Shireman et al for an Elderly Patient Being Treated with Warfarin |
| | | BleedScore of Serebruany and Atar for Classifying Bleeding Events |
| Antithrombin III Deficiency |
| | | Antithrombin III Replacement Therapy |
| | | Indications for Measuring Antithrombin III Levels |
| Thrombotic Thrombocytopenia Purpura (TTP) and Hemolytic-Uremic Syndrome (HUS) |
| | | Predicting Survival in Thrombotic Thrombocytopenia Purpura with Laboratory Tests |
| | | Clinical Severity Scoring System of Rose and Eldor for TTP or HUS |
| | | Prognostic Factors of Pereira et al in Thrombotic Thrombocytopenic Purpura and the Hemolytic Uremic Syndrome |
| | | Deficiency in ADAMTS13 and Thrombotic Thrombocytopenic Purpura |
| | | Recurrent or Familial Hemolytic-Uremic Syndrome or Membranoproliferative Glomerulonephritis in Factor H Deficiency |
| | | Criteria of Tuncer et al for Clinical Outcome After Treating a Patient with TTP-HUS |
| | | Modified Rose Index of the Canadian Apheresis Group for TTP or HUS |
| | | Index of Wyllie et al for Predicting Mortality in a Patient with TTP or HUS |
| | | Risk Factors of Oakes et al for Mortality in a Pediatric Patient with Postdiarrheal Hemolytic Uremic Syndrome |
| | | HIV-Related Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic Uremic Syndrome (HUS) |
| Antiphospholipid Thrombosis and Lupus Anticoagulant Syndromes |
| | | Laboratory Diagnosis of Antiphospholipid Syndromes |
| | | Clinical Syndromes Associated with Anticardiolipin Antibodies |
| | | Evaluation of a Patient with a Lupus Anticoagulant and a Prolonged Prothrombin Time (Hypoprothrombinemia-Lupus Anticoagulant Syndrome) |
| | | Catastrophic Antiphospholipid Syndrome (CAP, Asherson Syndrome) |
| | | Features of Antiphospholipid Antibody-Associated Cardiac Valve Disease |
| | | Features of Antiphospholipid Antibody-Associated Nephropathy |
| | | Features of Antiphospholipid Antibody-Associated Livedo Reticularis |
| | | Features of Antiphospholipid Antibody-Associated Thrombocytopenia |
| | | Sneddon Syndrome (Livedo Reticularis and Ischemic Cerebrovascular Disease) Associated with Antiphospholipid Antibodies |
| | | Updated International Consensus Criteria for the Diagnosis of the Antiphospholipid Syndrome (Sydney Criteria) |
| Sticky Platelet Syndrome |
| | | Sticky Platelet Syndrome |
| Indications to Evaluate a Patient for Hypercoagulability (Thrombophilia) |
| | | Indications to Evaluate a Patient for Hypercoagulability (Thrombophilia) |
| Heparin-Induced Thrombocytopenia (HIT) |
| | | Heparin-Induced Thrombocytopenia Types I and II |
| | | Score of Pouplard et al for Estimating the Likelihood of Heparin-Induced Thrombocytopenia |
| | | Testing Algorithm for the Diagnosis of Heparin-Induced Thrombocytopenia |
| | | Therapy for Heparin-Induced Thrombocytopenia with Lepirudin (Refludan) in a Patient with Normal Renal Function |
| | | Therapy for Heparin-Induced Thrombocytopenia with Lepirudin (Refludan) in a Patient with Renal Insufficiency |
| | | Scoring System of Chong and Chong for Diagnosis of Heparin-Induced Thrombocytopenia (HIT) |
| | | Acute Systemic Reaction Following Administration of Intravenous Heparin |
| | | Conditions That May Mimic Heparin-Induced Thrombocytopenia (Pseudo-HIT) |
| | | Score of Warkentin and Heddle for the Diagnosis of Heparin-Induced Thrombocytopenia (HIT) |
| | | White Clot Syndrome in Heparin-Induced Thrombocytopenia (HIT) |
| | | Skin Lesions at Subcutaneous Heparin Injection Sites in a Patient with Heparin-Induced Thrombocytopenia (HIT) |
| | | Acute Adrenal Hemorrhage in a Patient with Heparin-Induced Thrombocytopenia (HIT) |
| Disseminated Intravascular Coagulation (DIC) |
| | | DIC Score of Bick |
| | | Monitoring Therapy for DIC with the DIC Score |
| | | DIC Score of Yu et al |
| | | DIC Scoring Algorithm of the ISTH Scientific and Standardization Committee |
| | | Kasabach-Merritt Phenomenon and Vascular Tumors in Children |
| | | Risk Factors for Disseminated Intravascular Coagulation (DIC) in a Trauma Patients |
| | | Criteria of the ISTH Scientific and Standardization Committee for Non-Overt DIC |
| | | The New Japanase Diagnostic Criteria for Disseminated Intravascular Coagulation in Critically Ill Patients |
| | | Criteria of Shirahata et al for Disseminated Intravascular Coagulation (DIC) in a Newborn Infant |
| | | Criteria of Kobayashi et al for Disseminated Intravascular Coagulation (Japanese Diagnostic Criteria) |
| | | Classification of Disseminated Intravascular Coagulation (DIC) Based on the Degree of Compensation in the Production of Coagulation Factors and Platelets |
| Thrombolytic Therapy |
| | | Contraindications to Thrombolytic Therapy |
| | | Bleeding Risk after Contemporary Thrombolytic Therapy Following Myocardial Infarction |
| | | Thrombolytic Predictive Instrument for Intracranial Hemorrhage |
| | | Thrombolytic Predictive Instrument for Major Bleeding |
| | | Dosing an Infusion of Abbokinase Brand Urokinase for a Patient with Pulmonary Embolism |
| | | Determining the Dose of Alteplase for Thrombolysis in Acute Stroke |
| | | Determining the Accelerated Infusion Dose of Alteplase for Thrombolysis in Acute Myocardial Infarction |
| | | Determining the Dose of Alteplase for a 3 Hour Infusion After Acute Myocardial Infarction |
| | | Model of Sloan et al for Risk of 30-Day Mortality Associated with Intracranial Hemorrhage Associated with Thrombolysis Therapy After Acute Myocardial Infarction |
| Anticoagulant Therapy to Prevent Stroke in Patients with Atrial Fibrillation |
| | | Guidelines of Thomson et al for Anticoagulant Therapy to Prevent Stroke in Patients with Atrial Fibrillation |
| | | Prophylactic Therapy to Reduce the Risk of Stroke in Patients with Atrial Fibrillation |
| | | Algorithm of Hardman and Cowie for Anticoagulation Therapy in Non-Rheumatic Atrial Fibrillation |
| | | Rule of van Walraven et al for Using Aspirin as Stroke Prophylaxis in Patients with Non-Valvular Atrial Fibrillation |
| Immune Thrombocytopenic Purpura (ITP) |
| | | Clinical Staging of Immune Thrombocytopenic Purpura |
| | | Classification of Holt for the Response to Therapy in a Child with Immune Thrombocytopenic Purpura (ITP) |
| | | Risk Factors of Schattner and Bussel for Mortality in Immune Thrombocytopenic Purpura (ITP) |
| | | Criteria of Stasi et al for Response to Therapy for Immune Thrombocytopenic Purpura (ITP) |
| | | Criteria of Blanchette et al for Bleeding Severity in a Child with Acute Idiopathic Thrombocytopenic Purpura (ITP) |
| | | Criteria of Bolton-Maggs and Moon for Bleeding Severity in a Child with Acute Idiopathic Thrombocytopenic Purpura (ITP) |
| | | Grading Criteria of Buchanan and Adix for Hemorrhage in a Child with Acute Idiopathic Thrombocytopenic Purpura (ITP) |
| | | Criteria of Medeiros and Buchanan for Major Hemorrhage in a Child with Acute Idiopathic Thrombocytopenic Purpura (ITP) |
| | | Outcomes of Portielje et al for an Adult with Idiopathic Thrombocytopenic Purpura |
| | | Criteria of Lacey and Penner for Idiopathic Thrombocytopenic Purpura (ITP) in the Adult |
| | | Bleeding Score of Godeau et al for a Patient with Autoimmune Thrombocytopenic Purpura |
| | | Bleeding Score of Khellaf et al for a Patient with Autoimmune Thrombocytopenic Purpura |
| Post-Thrombotic (Post-Phlebitic) Syndrome |
| | | The Post-Thrombotic Score (PTS) of Brandjes et al |
| | | The Post-Thrombotic Score (PTS) of Villalta et al |
| | | Criteria of Goldenberg et al for the Post-Thrombotic Syndrome in a Child |
| | | Clinical Features of Upper Extremity Post-Thrombotic Syndrome |
| Bleeding Associated with Nontherapeutic Use of Coumarin or Indandione Compounds |
| | | Criteria for Superwarfarin-induced Coagulopathy |
| | | Factitious Bleeding Disorder Associated with Self-Administration of Warfarin |
| von Willebrand's Disease (VWD) |
| | | Criteria for Acquired von Willebrand's Disease |
| | | Types of von Willebrand's Disease Based on Laboratory Test Findings |
| | | Criteria of the Hospital for Sick Children for Significant Mucocutaneous Bleeding in a Patient with von Willebrand's Disease |
| | | Criteria of theInternational Society on Thrombosis and Haemostasis (ISTH) for Significant Mucocutaneous Bleeding in a Patient with von Willebrand's Disease |
| Interpretation of Coagulation Factor Tests |
| | | Evaluation of PT and aPTT Test Results |
| | | Using Factor V and VII Levels in the Evaluation of the Bleeding Patient |
| Reversal of the Coagulopathy Associated with Warfarin/Coumadin Therapy |
| | | Use of Vitamin K to Reverse Warfarin-Associated Coagulopathy |
| | | Use of Prothrombin Complex Concentrate to Reverse the Effects of a Vitamin K Antagonist |
| | | Use of Fresh Frozen Plasma (FFP) to Reverse the Effects of a Vitamin K Antagonist |
| | | Protocol of Goodnough et al for Reversal of a Prolonged INR with Recombinant Factor VIIa (rFVIIa) |
| Uremic Bleeding |
| | | Therapeutic Options for a Patient with Uremic Bleeding |
| | | Clinical Features of Uremic Bleeding |
| Coagulopathies in Oncology Patients |
| | | Bleeding Risk Index of Elting et al in Patients with Malignant Lymphoma or Solid Tumors |
| | | Deep Vein Thrombosis Associated with Carcinoma (Trousseau's Syndrome) |
| | | Risk Factors of Blom et al for Venous Thrombosis in a Patient with a Malignancy |
| | | Risk Factors of Khorana et al for Venous Thromboembolism in a Patient with Cancer Starting Chemotherapy |
| | | Risk Factors of Khorana et al for Thromboembolism in a Hospitalized Cancer Patient with Neutropenia |
| | | Algorithm of Gerber et al for Managing a Patient with Venous Thromboembolism and a Primary or Metastatic Brain Tumor |
| | | Risk Factors of Bohlius et al for Thrombosis Associated with Recombinant Human Erythropoietin Therapy in a Patient with Cancer |
| | | Risk Factors of Chew et al for Venous Thromboembolism in a Woman with Breast Cancer |
| | | Risk Factors of Tesselaar and Osanto for Venous Thromboembolism in a Patient with Lung Cancer |
| | | Risk Score of Kim et al for Fatal Intracranial Hemorrhage in a Patient with Acute Leukemia |
| Recombinant Activated Protein C (APC) |
| | | Contraindications to the Use of Recombinant Protein C |
| Disorders of Fibrinogen |
| | | Algorithm of Cunningham et al for Laboratory Testing in a Patient with Suspected Dysfibrinogenemia |
| | | Clinical and Laboratory Features of Congenital Afibrinogenemia or Hypofibrinogenemia |
| | | Clinical and Laboratory Features of Congenital Dysfibrinogenemia |
| | | Clinical and Laboratory Features of Fibrinogen Brescia (Familial Hypofibrinogenemia with Hepatocytic Inclusion Bodies) |
| | | Classification of Medicina et al for Hereditary Disorders of Fibrinogen Associated with Hepatocytic Inclusion Bodies |
| Thrombosis Associated with Organ Transplantation |
| | | Risk Factors of Oh et al for Early and Late Hepatic Artery Thrombosis After Liver Transplantation |
| | | Risk Factors of Vivarelli et al for Hepatic Artery Thrombosis or Stenosis After Liver Transplantation |
| Drug Therapy to Inhibit Platelet Function |
| | | Aspirin Resistance |
| | | Contraindications to Aspirin Therapy |
| Coagulopathy Associated with Liver Disease |
| | | Treatment of a Bleeding Patient with Liver Failure |
| | | Hemostatic Defects in a Patient with End-Stage Liver Disease |
| Anticoagulation During Cardiopulmonary Bypass (CPB) |
| | | Protocol of Poetzsch and Madlener for Anticoagulation During Cardiopulmonary Bypass Using Danaparoid Sodium |
| | | Protocol of Poetzsch and Madlener for Anticoagulation During Cardiopulmonary Bypass Using Lepirudin (r-Hirudin) |
| Protamine Sulfate |
| | | Reversal of Unfractionated Heparin Therapy with Protamine Sulfate |
| | | Patients to Screen for Allergy to Protamine Sulfate |
| | | Types of Adverse Reactions Following Administration of Protamine Sulfate |
| | | Reversal of Dalteparin Sodium Overdosage with Protamine Sulfate |
| Fibrinolysis Inhibitors |
| | | Protocol of Cole et al for Use of Aprotinin in Children Undergoing Spinal Surgery |
| Low Molecular Weight Heparin Therapy |
| | | Prophylactic Dosage Regimens of Dalteparin Sodium for Hip Replacement Surgery |
| Thrombosis of a Cerebral Sinus |
| | | Risk Factors of DeVeber et al for Cerebral Sinovenous Thrombosis in Children |
| Bleeding Disorders in Trauma Patients |
| | | Risk Factors of Hanes et al for Thrombocytopenia in a Trauma Patient in the Intensive Care Unit (ICU) |
| | | Risk Factors of Ferrara et al for Coagulopathy and Death Following Massive Transfusion for Trauma |
| Fibrinolysis |
| | | Conditions Associated with Systemic Fibrinolysis |
| | | Features of a Hereditary Deficiency of Alpha-2 Antiplasmin |
| | | Plasminogen Activator Inhibitor (PAI) Concentration and Genotype |
| Effects on Coagulation Associated with Herbal or Dietary Supplements |
| | | Effects on Coagulation Associated with Herbal or Dietary Supplements |
| Replacement of a Coagulation Factor Deficiency |
| | | Models of Holland and Brooks for Predicting the Impact of Fresh Frozen Plasma (FFP) Transfusion on the INR |
| | | Calculating Amount of Factor Replacement |
| | | Data on Coagulation Factors |
| | | Increment in Coagulation Factor after Transfusion |
| Recombinant Factor VIIa (rFVIIa) Therapy |
| | | Therapy with Recombinant Factor VIIa in a Patient with a Factor VIII or IX Inhibitor |
| | | Risk Factors Associated with Thrombosis Following Recombinant Factor VIIa Therapy |
| | | Use of Recombinant Factor VIIa in a Patient with Congenital Factor VII Deficiency |
| | | Therapy with Recombinant Factor VIIa for Uncontrollable Hemorrhage in a Patient with a Qualitative or Quantitative Platelet Disorder |
| | | Therapy with Recombinant Factor VIIa for Uncontrollable Hemorrhage in a Patient with Liver Disease, Trauma or Recent Surgery |
| Drug-Induced Thrombocytopenia (DIT) |
| | | Criteria of George et al for the Diagnosis of Drug-Induced Thrombocytopenia |
| |
| TOP |